Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management, Finds GBI Research12 Jun 2012 • by Natalie Aster
The market for pain management therapeutics is comprised of therapies such as opioids, non-steroidal anti-inflammatory drugs (NSAIDs), local anesthetics, tricyclic antidepressants and anticonvulsants. Opioids, which represent the largest pain therapy class, can cause side effects such as nausea, vomiting, constipation and drowsiness, and even severe respiratory depression. Opioids are also often viewed in a negative light for their addictive qualities. NSAIDs in turn can cause gastrointestinal upsets, increase cardiovascular risks, and cause kidney and liver damage.
However, the future may hold some hope for chronic pain sufferers. The unmet need for safer and more efficient drugs has resulted in substantial R&D interest in treating pain conditions. The current R&D pipeline for pain management has 282 trials in different stages of discovery and development. Neuropathic pain, currently accounting for almost half of the total pain management therapeutics market, is the key therapy focus area in the current development pipeline. According to the report “Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management” by GBI Research, more than 50% of the total trials for pain management therapeutics are in Phase III and Phase II research, which indicates that some new drug candidates will emerge in the near future.
Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management
Published: May, 2012
Price: US$ 3.500,00
Current competition between chronic pain therapeutics is strong, as many treatment options for chronic pain are available, meaning that lower market potential is available for any new entrants without innovative "first-in-class" drugs or disease-modifying mechanisms of action that can show improved overall survival, safety and efficacy. Therefore, new drug delivery systems look to favor novel techniques such as intravenous infusions, time-release transdermal skin patches, nasal sprays and inhaled aerosols. GBI Research estimates that the global pain management market was worth approximately $28.6 billion in 2010. Improved diagnosis of pain indications, coupled with blockbuster sales of Lyrica (pregabalin) and Cymbalta (duloxetine HCl), are expected to drive the pain therapeutics market in the future. While these two top-selling drugs are expected to face patent expiries in the forecast period, the healthy development pipeline for pain management reflects positive prospects for the growth of the market in the future.
More information can be found in the report “Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management” by GBI Research.
To order the report or ask for sample pages contact firstname.lastname@example.org